Enantioselective synthesis of (2-pyridyl)alanines via catalytic hydrogenation and application to the synthesis of L-azatyrosine

Organic Letters

Volumn 3, Issue 20, 2001, Pages 3157-3159

  Adamczyk, Maciej ^a   Akireddy, Srinivasa Rao ^a   Reddy, Rajarathnam E ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRIDYL ALANINE; 2-PYRIDYL ALANINE; ALANINE; ANTINEOPLASTIC ANTIBIOTIC; AZATYROSINE; BETA-(5-HYDROXY-2-PYRIDYL)ALANINE; DRUG DERIVATIVE; HYDROGEN; PYRIDINE DERIVATIVE;

ARTICLE; CATALYSIS; CHEMISTRY; STEREOISOMERISM; SYNTHESIS;

ALANINE; ANTIBIOTICS, ANTINEOPLASTIC; CATALYSIS; HYDROGEN; PYRIDINES; STEREOISOMERISM;

EID: 0035807552     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol016455q     Document Type: Article

References (52)

1. (a) Barret, G. C. Chemistry and Biochemistry of the Amino Acids: Chapman and Hall: London, 1985.
2. (b) Amino Acids, Peptides and Proteins; The Chemical Society: Cambridge, 1968-1991; Vols. 1-22.
3. Greenstein, J. P.; Wintz, M. Chemistry of the Amino Acids; Robert E. Krieger: FL, 1984; Vols. 1-3.
4. (a) Roberts, D. C.; Vellaccio, F. The Peptides; Academic Press: New York, 1983; Vol. 5, pp 341-449.
5. (b) Wilson, M. J.; Hatfield, D. L. Biochim. Biophys. Acta 1984, 781, 205-215.
6. Lea, P. J.; Norris, R. D. Phytochemistry 1976, 15, 585-595.
7. Coppola, G. M.; Schuster, H. F. Asymmetric Synthesis: Construction of Chiral Molecules using Amino Acids; John Wiley & Sons: New York, 1987.
8. (b) Hanessian, S. Total Synthesis of Natural Products: The Chiron Approach; Pergamon Press: Oxford, 1983.
9. Hsieh, K.; Jorgensen, E. C. J. Med. Chem. 1979, 22, 1199-1206.
10. Sullivan, P. T.; Kester, M.; Norton, S. J. J. Med. Chem. 1968, 11, 1172-1176.
11. Shimeno, H.; Soeda, S.; Nagamatsu, S. H. Chem. Pharm. Bull. 1977, 25, 2983-2987.
12. (a) Inouye, S.; Shomura, T.; Ogawa, Y.; Watanabe, H.; Yoshida, J.; Niida, T. Chem. Pharm. Bull. 1975, 23, 2669-2677.
13. (b) Izawa, M.; Takayama, S.; Shindo-Okada, N.; Doi, S.; Kimura, M.; Katsuki, M., Nishimura, S. Cancer Res. 1992, 52, 1628-1630 and references therein.
14. (a) Japanese Patent JP 60/130591 A2, 1985.
15. (b) European Patent EP 98609/A2, 1984.
16. Rivier, J. E.; Porter, J.; Rivier, C. L.; Perrin, M.; Corrigan, A.; Hook, W. A.; Siraganian, R. P.; Vale, W. W. J. Med. Chem. 1986, 29, 1846-1851.
17. Folkers, K.; Bowers, C. Y.; Kubiak, T. M.; Stepinski, J. U.S. Patent 4504414, 1985.
18. (a) Hoes, C.; Raap, J.; Bloemhoff, W.; Kerling, K. E. T. J. R. Neth. Chem. Soc. 1980, 99, 99-104.
19. (b) Cooper, M. S.; Seton, A. W.; Stevens, M. F. G.; Westwell, A. D. Bioorg. Med. Chem. Lett. 1996, 6, 2613-2616.
20. (a) Ye, B.; Otaka, A.; Burke, T. R., Jr. Synlett 1996, 459-460.
21. (b) Ye, B.; Burke, T. R., Jr. J. Org. Chem. 1995, 60, 2640-2641.
22. (a) Croce, P. D.; Rosa, C. L., Pizzatti, E. Tetrahedron: Asymmetry 2000, 11, 2635-2642.
23. (b) Myers, A. G.; Gleason, J. L. J. Org. Chem. 1996, 61, 813-815.
24. Schow, S. R.; DeJoy, S. Q.; Wick, M. M.; Kerwar, S. S. J. Org. Chem. 1994, 59, 6850-6852.
25. (a) Jones, S. W.; Palmer, C. F.; Paul, J. M.; Tiffin, P. D. Tetrahedron Lett. 1999, 40, 1211-1214.
26. (b) Dobler, C.; Kreuzfeld, H.-J.; Michalik, M.; Krause, H. W. Tetrahedron: Asymmetry 1996, 7, 117-125.
27. Cativiela, C.; Mayoral, J. A.; Melendez, E.; Oro, L. A.; Pinillos, M. T.; Uson, R. J. Org. Chem. 1994, 49, 2502-2504.
28. Bozell, J. J.; Vogt, C. E.; Gozum, J. J. Org. Chem. 1991, 56, 2584-2487.
29. (e) Adamczyk, M.; Akireddy, S. R.; Reddy, R. E. Org. Lett. 2000, 2, 3421-3423.
30. (a) Noyori, R. Asymmetric Catalysis in Organic Synthesis; Wiley and Sons: New York, 1994; pp 16-94.
31. (b) Takaya, H.; Ohta, T.; Noyori, R. In Catalytic Asymmetric Hydrogenation; Ojima, I., Ed.; VCH Publishers: Weinheim, 1993; pp 1-39.
32. (a) Chung, D. L.; Brandt-Kauf, P.; Murphy, R. B.; Nishimura, S.; Yamaizumi, Z.; Weinstein, I. B.; Pincus, M. R. Anticancer Res. 1991, 11, 1373-1378.
33. (b) Fujita-Yoshigaki, J.; Yokoyama, S.; Shindo-Okada, N.; Nishimura S. Oncogene 1992, 7, 2019-2024.
34. Campa, M. J.; Glickman, J. F.; Yamamoto, K.; Chang, K.-J. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7654-7658.
35. Kyprianou, N.; Taylor-Papadimitriou, J. Oncogene 1992, 7, 57-63.
36. (e) Nomura, T.; Ryoyama, K.; Okada, G.; Matano, S.; Nakamura, S.; Kameyama, T. Jpn. J. Cancer Res. 1992, 83, 851-858.
37. (f) Shindo-Okada, N.; Makabe, O.; Nagahara, H.; Nishimura, S. Mol. Carcinog. 1989, 2, 159-167.
38. (2-Pyridyl)dehydroamino acid derivatives 1a-b were prepared from commercially available pyridine-2-carboxaldehyde and 5-bromo-pyridine-2-carboxaldehyde, respectively, in 78-89% yield by treatment with N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester in the presence of N,N,N′,N′-tetramethylguanidine (TMG) in THF at room temperature for 6 h.
39. Caron, S.; Do, N. M.; Sieser, J. Tetrahedron Lett. 2000, 41, 2299-2302.
40. For a review on the asymmetric hydrogenation using pnospnme ligands, see: Knowles, W. S. Acc. Chem. Res. 1983, 16, 106-112.
41. 19F NMR.
42. The absolute configuration of the newly generated chiral center in 4a using (R,R)-6 catalyst was determined to be (5) by cleavage of protective groups to the corresponding known α-amino acid and comparison of its rotation; see: ref 9a.
43. Aoyagi, Y.; Abe, T.; Ohta, A. Synthesis 1997, 891-894.
44. For synthesis of azatyrosine [(5-hydroxy-2-pyridyl)glycine], see: (a) Norton, S. J.; Skinner, C. G.; Shive, W. J. Org. Chem. 1970, 26, 1495-1498.
45. (b) Norton, S. J.; Sullivan, P. T. J. Heterocycl. Chem 1970, 7, 699-702.
46. Herdeis, C.; Gebhard, R. Heterocycles 1986, 24, 1019-1024.
47. Schow, S. R.; Deloy, S. Q.; Wick, M. M.; Kerwar, S. S. J. Org. Chem. 1994, 59, 6850-6852.
48. Ye, B.; Burke, T. R. J. Org. Chem. 1995, 60, 2640-2641.
49. (e) Coopre, M. S.; Seton, A. W.; Stevens, M. F. G.; Westwell, A. D. Bioorg. Med. Chem. Lett. 1996, 6, 2613-2616.
50. (f) Myers, A. G.; Gleason, J. L. J. Org. Chem. 1996, 60, 813-815.
51. The enantiomeric excess (% ee) of (5)-(-)-10 before and after crystallization was determined by converting to Mosher's amide in three steps: see ref 18 for details.
52. Preparative reversed phase HPLC was carried out on a Waters, Symmetry, C18, 7.0 μ, 40 × 100 mm column using 2:98 MeCN/0.1% aqueous trifluoroacetic acid. 25 mL/min at 225 nm.